The combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy for breast cancer: a meta-analysis of randomized evidence

Abstract

Abstract:ObjectiveTo compare the efficacy and safety of trastuzumab versus the combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy in HER2positive breast cancer. MethodsWe searched PubMed, MEDLINE, The Cochrane Library, Web of Science, CNKI, Wanfang datebase and the abstracts of major international conferences in recent 5 years to identify randomized controlled trials which met the inclusion and exclusion criteria. Study selection and analyses were undertaken according to the Cochrane Handbook. Metaanalysis was performed using RevMan 5.0 software. ResultsFour trials were identified with 779 eligible patients. The results of metaanalyses showed that the rate of pathological complete response was significantly higher in the group receiving rastuzumab and tlapatinib than that in the group with trastuzumab alone (53.3%vs 38.8%，RR=1.39, 95 %CI： 1.201.63; P<0.001). No statistical differences were observed in regarding adverse events among patients receiving trastuzumab or the combination of trastuzumab and lapatinib, except the grade ⅢⅣ diarrhea (2.2%vs 25.6%，RR=11.54, 95%CI： 5.6923.41; P<0.001). ConclusionThe combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy in HER2positive breast cancer is more effective, without more adverse reactions except diarrhea; it ia an effective and safe treatment.

Key words:Breast neoplasms,Neoadjuvant therapy,Metaanalysis,Trastuzumab,Lapatinib

CAO Min, WU Yun-Qiang, LU Ning, HUANG Jian-Guo. The combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy for breast cancer: a meta-analysis of randomized evidence[J]. Journal of International Oncology, 2015, 42(4): 296-273.

References

［1］ Ross JS, Slodkowska EA, Symmans WF, et al. The HER2 receptor and breast cancer: ten years of targeted antiHER2 therapy and personalized medicine［J］. Oncologist, 2009, 14(4): 320368. ［2］ Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutionalbased review［J］. J Clin Oncol, 2010, 28(1): 9298. ［3］ Valachis A, Mauri D, Polyzos NP, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2positive breast cancer: a systematic review and metaanalysis［J］. Breast, 2011, 20(6): 485490. ［4］ Viani GA, Afonso SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of her2positive early breast cancer: a metaanalysis of published randomized trials［J］. BMC Cancer, 2007, 7: 153. ［5］ Harris CA, Ward RL, Dobbins TA, et al. The efficacy of HER2targeted agents in metastatic breast cancer: a metaanalysis［J］. Ann Oncol, 2011, 22(6): 13081317. ［6］ Cetin B, Benekli M, Turker I, et al. Lapatinib plus capecitabine for HER2positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)［J］. J Chemother, 2014, 26(5): 300305. ［7］ Jackisch C, Scappaticci FA, Heinzmann D, et al. Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation［J］. Future Oncol, 2014, 8(28): 6171. ［8］ Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2positive locally advanced breast cancer (NOAH): followup of a randomised controlled superiority trial with a parallel HER2negative cohort［J］. Lancet Oncol, 2014, 15(6): 640647. ［9］ Badwe R, Hawaldar R, Parmar V, et al. Singleinjection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial［J］. J Clin Oncol, 2011, 29(21): 28452851. ［10］ Higgins JP, Altman DG, Gtzsche PC, et al. The Cochrane Collaboration′s tool for assessing risk of bias in randomised trials［J］. BMJ, 2011, 343:d5928. ［11］ Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2positive early breast cancer (NeoALTTO): a randomised, openlabel, multicentre, phase 3 trial［J］. Lancet, 2012, 379(9816): 633640. ［12］ Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2positive operable breast cancer: results of the randomized phase Ⅱ CHERLOB study［J］. J Clin Oncol, 2012, 30(16): 19891995. ［13］ Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2positive operable breast cancer(NSABP protocol B41): an openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2013, 14(12): 11831192. ［14］ Holmes FA, Espina V, Liotta LA, et al. Pathologic complete response after preoperative antiHER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling［J］. BMC Res Notes, 2013, 6: 507. ［15］ Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER2overexpressing and trastuzumabtreated breast cancer cells［J］. Cancer Res, 2006, 66(3): 16301639. ［16］ Wang YC, Morrison G, Gillihan R, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2positive breast cancersrole of estrogen receptor and HER2 reactivation［J］. Breast Cancer Res, 2011, 13(6): R121. ［17］ Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2positive metastatic breast cancer: final results from the EGF104900 Study［J］. J Clin Oncol, 2012, 30(21): 25852592. ［18］ Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2positive breast cancer (NeoSphere):a randomised multicentre, openlabel, phase 2 trial［J］. Lancet Oncol, 2012, 13(1): 2532. ［19］ Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer［J］. N Engl J Med, 2012, 366(2): 109119. ［20］ Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups［J］. J Clin Oncol, 2011, 29(25): 33513357. ［21］ Doval DC, Dutta K, Batra U, et al. Neoadjuvant chemotherapy in breast cancer: review of literature［J］. J Indian Med Assoc, 2013, 111(9): 629631.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Xu Fang, Zhu Wentian.Progress in adjuvant therapy of hepatocellular carcinoma complicated with microvascular invasion[J]. Journal of International Oncology, 2023, 50(5): 304-309.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.